Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.
about
Molecular determinants of species specificity in the coronavirus receptor aminopeptidase N (CD13): influence of N-linked glycosylation.HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIVBioinformatic analysis of HIV-1 entry and pathogenesis.The influence of N-linked glycans on the molecular dynamics of the HIV-1 gp120 V3 loop.Evolution of the uniquely adaptable lentiviral envelope in a natural reservoir host.Optimized expression and specific activity of IL-12 by directed molecular evolution.Comparison of HPLC/ESI-FTICR MS versus MALDI-TOF/TOF MS for glycopeptide analysis of a highly glycosylated HIV envelope glycoprotein.Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways.R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models.A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer.Functional properties of the HIV-1 subtype C envelope glycoprotein associated with mother-to-child transmissionSelection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels.The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.Determinants of syncytium formation in microglia by human immunodeficiency virus type 1: role of the V1/V2 domainsSimian-human immunodeficiency virus containing a human immunodeficiency virus type 1 subtype-E envelope gene: persistent infection, CD4(+) T-cell depletion, and mucosal membrane transmission in macaquesQuintuple deglycosylation mutant of simian immunodeficiency virus SIVmac239 in rhesus macaques: robust primary replication, tightly contained chronic infection, and elicitation of potent immunity against the parental wild-type strain.Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys.Equine infectious anemia virus genomic evolution in progressor and nonprogressor ponies.During readaptation in vivo, a tissue culture-adapted strain of feline immunodeficiency virus reverts to broad neutralization resistance at different times in individual hosts but through changes at the same position of the surface glycoprotein.Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.Conserved, N-linked carbohydrates of human immunodeficiency virus type 1 gp41 are largely dispensable for viral replication.Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.Feline immunodeficiency virus-infected cat sera associated with the development of broad neutralization resistance in vivo drive similar reversions in vitro.The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.Increased sensitivity to broadly neutralizing antibodies of end-stage disease R5 HIV-1 correlates with evolution in Env glycosylation and charge.Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity.The role of the third beta strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012V3 loop-determined coreceptor preference dictates the dynamics of CD4+-T-cell loss in simian-human immunodeficiency virus-infected macaquesIdentification of two N-linked glycosylation sites within the core of the simian immunodeficiency virus glycoprotein whose removal enhances sensitivity to soluble CD4.Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection.Algal lectins as potential HIV microbicide candidatesConsistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaquesNeutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infantThe V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.Equine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype.Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120.Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable regionType-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positioFactors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1Characterization of HIV-1 envelope gp41 genetic diversity and functional domains following perinatal transmission.
P2860
Q24529180-B0779DE8-0FCA-4F55-9439-3B9E0905951CQ27497560-66863B68-1347-42BC-9128-FD41595DE92FQ27693321-1408510A-C1A0-471D-99B5-04D79C0DED3DQ30356350-BD0C655C-D3C0-477B-8131-961EA750675EQ31034710-DCFDE7A8-5F00-4381-BFD1-21022D4C5B9CQ33185720-CC4DD36E-1AF2-431A-BA2C-719D6B97769AQ33345100-25A6F93A-2AFB-4269-A633-0908C4826DB2Q33504599-5B8B7A0B-7366-486C-BDDD-1A9B5AD7018CQ33640144-0ED88549-AFD0-4FF3-9191-60AC0A83088BQ33725702-22075BF5-CB80-4DA0-968B-B8ACDC82166FQ33749206-CC3EDD33-826C-4E69-A202-D25F96F64004Q33780649-D6551298-EACC-4FD7-A99F-D1697201EF52Q33788792-E1EB50A9-D2D8-4150-9A9E-651B8D6128E0Q33796067-0B598D16-EB62-4DDB-AE3A-0D0277C11705Q33810425-C06C9B72-82A5-47A2-8C58-A82B63B9C4B5Q33839044-8B8EFA2C-751B-465F-8ACE-F9D40ABE327FQ33839485-D842B585-36EE-45EE-868F-1AC73E4C1947Q33840365-0E8340B0-2740-43A9-8D61-724212BD88F1Q33840406-23D87134-7538-4A9F-A16B-FD00DDCCD36EQ33843345-2354F7BE-E53C-448F-A56E-428B4A8213C0Q33849755-1110DDEA-3683-4D24-82A5-9B0DDD38E0D8Q33851094-C3050AA6-5B18-4806-AEBA-7E257B595C20Q33854938-0F5AAF4A-371D-4C84-8B8A-F2645AE2D367Q33883936-AA27F707-7B3F-48DA-91FE-1FEDAEBA169AQ33941033-356340A7-4119-44C0-9837-5744848A0E26Q33951963-0989E12F-43B5-41BD-995F-61A7C8A97567Q33953062-74658E10-2BA3-49D3-B38E-913CD9C5A53BQ33984326-1D0B23EF-67DB-479D-8567-0B3D3A99C90AQ33984371-89C29817-2DC3-4293-9A2F-CAE96AA27F17Q34203163-786887C6-3797-436F-B413-08B5F59CDC85Q34291727-197C6C10-B046-4C62-AA79-A861284AF1CFQ34301728-76DF4532-13CF-4961-97DB-2A5C8B6D86AEQ34301874-556EE517-99FE-4457-8903-12AC96F71415Q34317025-1F1AB7C4-FBCB-4A9E-A503-54E120D27514Q34349343-E3718D2E-D091-4DFC-8E8B-4F76F95E15C2Q34464860-E8BDC4AC-7F76-4674-B251-EC3892C0D038Q34471760-B9FCB727-E87A-4185-ABE9-ABCCE2DA19ACQ34583767-9818DF18-41F3-4022-AE5C-250660EA39C5Q34717733-9F2E9480-DF14-4D5C-9228-82E49BEA7D8CQ34899225-C8D08343-DDF6-4CF9-A793-381CFAED5108
P2860
Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Selection for neutralization r ...... modify N-linked glycosylation.
@en
Selection for neutralization r ...... modify N-linked glycosylation.
@nl
type
label
Selection for neutralization r ...... modify N-linked glycosylation.
@en
Selection for neutralization r ...... modify N-linked glycosylation.
@nl
prefLabel
Selection for neutralization r ...... modify N-linked glycosylation.
@en
Selection for neutralization r ...... modify N-linked glycosylation.
@nl
P2093
P2860
P1433
P1476
Selection for neutralization r ...... modify N-linked glycosylation
@en
P2093
P2860
P304
P407
P577
1999-07-01T00:00:00Z